BRCA1 and neoplasm: To evaluate the potential of using DNA-PKcsi to treat olaparib-resistant BRCA1-mutated ZNF251KD cells in vivo, we conducted an experiment where we treated tumor-bearing mice with PIK-75 and/or olaparib.